

Curriculum Vitae

HALIT FIRAT ERDEN, M.D.

EDUCATION

Istanbul University Cerrahpasa Medical Faculty Doctor of Medicine	Istanbul, Turkey 1984-1990
Haydarpasa Numune Research and Teaching Hospital Residency Training in Gynaecology and Obstetrics	Istanbul, Turkey 1990-1995
University of California, San Diego Postdoctoral Fellowship in Reproductive Endocrinology and Infertility	San Diego, CA 1995- 1997
Eastern Virginia Medical School- Jones Institute Visiting Fellow, IVF, Andrology, ICSI	Norfolk, VA Apr 1997- July1997
Cornell University Medical Center Visiting Fellow, Assisted Reproductive Technologies	Aug 1997- Sep 1997

EXPERIENCE

German Hospital IVF Specialist and Reproductive Endocrinologist Medical Director of IVF Clinic	Istanbul, Turkey Nov 1999-Nov 2009 Nov 1999-Nov 2009
Bahceci Women's Health and Infertility Clinic IVF Specialist and Reproductive Endocrinologist	Istanbul, Turkey Dec 2009-Oct 2012
German Hospital IVF Specialist and Reproductive Endocrinologist	Istanbul, Turkey Nov 2012 -Feb 2103
Private Practice & Acibadem Maslak Hospital Affiliation IVF Specialist and Reproductive Endocrinologist	Istanbul, Turkey March 2013-Present

FIELDS OF INTEREST & EXPERT

Laparoscopic and Hysteroscopic Surgery (ADVANCED)
Obstetrical , Gynaecological, and Doppler Ultrasonography
Infertility Diagnosis and Treatment
Reproductive Immunology

Bio-identical Hormone Replacement

MEMBERSHIPS

Endocrine Society

American Society of Reproductive Medicine

American Association of Gynecologic Laparoscopists

European Society Human Reproduction

American Society of Reproductive Immunology

PUBLICATIONS

1. Klinefelter syndrome: does it confer a bad prognosis in treatment of nonobstructive azoospermia?
Bakircioglu ME, Ulug U, **Erden HF**, Tosun S, Bayram A, Ciray N, Bahceci M. Fertil Steril. 2011 Apr;95(5):1696-9. doi: 10.1016/j.fertnstert.2011.01.005. Epub 2011 Feb 4.
2. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial.
Sismanoglu A, Tekin HI, **Erden HF**, Ciray NH, Ulug U, Bahceci M. J Assist Reprod Genet. 2009 May;26(5):251-6. doi: 10.1007/s10815-009-9326-6. Epub 2009 Jul 23.
3. Outcome of assisted reproduction treatment in patients with endometrial thickness less than 7 mm.
Kumbak B, **Erden HF**, Tosun S, Akbas H, Ulug U, Bahçeci M. Reprod Biomed Online. 2009 Jan;18(1):79-84.
4. Frozen-thawed cleavage-stage embryo transfer cycles after previous GnRH agonist or antagonist stimulation.
Bahçeci M, Ulug U, **Erden HF**, Tosun S, Ciray N. Reprod Biomed Online. 2009 Jan;18(1):67-72.
5. Gonadotrophin therapy in combination with ICSI in men with hypogonadotrophic hypogonadism.
Bakircioglu ME, Erden HF, Ciray HN, Bayazit N, Bahçeci M. Reprod Biomed Online. 2007 Aug;15(2):156-60.

6. Comparison of preovulatory follicular concentrations of epidermal growth factor, insulin-like growth factor-I, and inhibins A and B in women undergoing assisted conception treatment with gonadotropin-releasing hormone (GnRH) agonists and GnRH antagonists.
Ulug U, Turan E, Tosun SB, Erden HF, Bahceci M.
Fertil Steril. 2007 Apr;87(4):995-8. Epub 2007 Feb 5.
7. Aging may adversely affect testicular sperm recovery in patients with Klinefelter syndrome.
Emre Bakircioglu M, Erden HF, Kaplancan T, Ciray N, Bener F, Bahceci M.
Urology. 2006 Nov;68(5):1082-6. Epub 2006 Nov 7.
8. Outcome of 1114 ICSI and embryo transfer cycles of women 40 years of age and over. Ciray HN, Ulug U, Tosun S, Erden HF, Bahceci M.
Reprod Biomed Online. 2006 Oct;13(4):516-22.
9. Efficiency of changing the embryo transfer time from day 3 to day 2 among women with poor ovarian response: a prospective randomized trial.
Bahceci M, Ulug U, Ciray HN, Akman MA, Erden HF.
Fertil Steril. 2006 Jul;86(1):81-5. Epub 2006 May 23.
10. Impact of coasting in patients undergoing controlled ovarian stimulation with the gonadotropin-releasing hormone antagonist cetrorelix.
Bahceci M, Ulug U, Tosun S, Erden HF, Bayazit N.
Fertil Steril. 2006 May;85(5):1523-5. Epub 2006 Mar 29.
11. Elevated oestradiol concentrations are not associated with increased first trimester miscarriage rates of singleton gestations conceived by assisted conception treatment. Bahçeci M, Ulug U, Erden HF, Mesut A, Jozwiak EA.
Reprod Biomed Online. 2006 Jan;12(1):33-8.
12. The reproductive performance of women with hypogonadotropic hypogonadism in an in vitro fertilization and embryo transfer program.
Ulug U, Ben-Shlomo I, Tosun S, Erden HF, Akman MA, Bahceci M.
J Assist Reprod Genet. 2005 Apr;22(4):167-71.
13. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
Bahçeci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA.
J Reprod Med. 2005 Feb;50(2):84-90.
14. Endometrial fluid visualized through ultrasonography during ovarian stimulation in IVF cycles impairs the outcome in tubal factor, but not PCOS, patients. Akman MA, **Erden HF**, Bahceci M.
Hum Reprod. 2005 Apr;20(4):906-9. Epub 2005 Jan 7.
15. Prenatal karyotypes of fetuses conceived by intracytoplasmic sperm injection.
Jozwiak EA, Ulug U, Mesut A, **Erden HF**, Bahçeci M.
Fertil Steril. 2004 Sep;82(3):628-33.

16. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles.
Ulug U, Ben-Shlomo I, Turan E, **Erden HF**, Akman MA, Bahceci M.
Reprod Biomed Online. 2003 Jun;6(4):439-43.
17. Can luteal phase estradiol levels predict the pregnancy outcome in in vitro fertilization cycles of good responders whose excess embryos yield blastocysts? Akman MA, **Erden HF**, Bener F, Liu JE, Bahceci M.
Fertil Steril. 2002 Mar;77(3):638-9.
18. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles.
Ulug U, Bahceci M, **Erden HF**, Shalev E, Ben-Shlomo I.
Hum Reprod. 2002 Feb;17(2):310-3.
19. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Akman MA, **Erden HF**, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Hum Reprod. 2001 May;16(5):868-70.
20. Addition of GnRH antagonist in cycles of poor responders undergoing IVF.
Akman MA, **Erden HF**, Tosun SB, Bayazit N, Aksoy E, Bahceci M.
Hum Reprod. 2000 Oct;15(10):2145-7.
21. Corticotropin-releasing factor inhibits luteinizing hormone-stimulated P450c17 gene expression and androgen production by isolated thecal cells of human ovarian follicles. **Erden HF**, Zwain IH, Asakura H, Yen SS.
J Clin Endocrinol Metab. 1998 Feb;83(2):448-52.